NVS: Novartis AG Stocks News on October 16, 2025

Cell and Gene Therapy Drug Delivery Research Report 202-2035: Rising Prevalence of Chronic and Genetic Disorders and Demand for Targeted Therapeutic Delivery Solutions Fuel Advances

NVS

GlobeNewswire

a day ago

Cell and Gene Therapy Drug Delivery Research Report 202-2035: Rising Prevalence of Chronic and Genetic Disorders and Demand for Targeted Therapeutic Delivery Solutions Fuel Advances

Non-Small Cell Lung Cancer Analysis Report 2025: Market Dominated by Roche, AstraZeneca, Merck, and Novartis, Fueled by Immuno-Oncology, Targeted Therapies, and Strategic Pipeline Collaborations

NVS

GlobeNewswire

a day ago

Non-Small Cell Lung Cancer Analysis Report 2025: Market Dominated by Roche, AstraZeneca, Merck, and Novartis, Fueled by Immuno-Oncology, Targeted Therapies, and Strategic Pipeline Collaborations

Varicella Zoster Virus Infection Treatment Research Report 2025: Market Dominated by Merck, GSK, Pfizer, and Novartis by Utilizing Regional Biotech Expansion and Global Immunization Partnerships

NVS

GlobeNewswire

a day ago

Varicella Zoster Virus Infection Treatment Research Report 2025: Market Dominated by Merck, GSK, Pfizer, and Novartis by Utilizing Regional Biotech Expansion and Global Immunization Partnerships

Vernal Keratoconjunctivitis Research Report 2025: Market Led by Novartis, Alcon, and Santen, Innovation, Biologic Therapies, and Expanding Generics Drive Competitive Differentiation

NVS

GlobeNewswire

a day ago

Vernal Keratoconjunctivitis Research Report 2025: Market Led by Novartis, Alcon, and Santen, Innovation, Biologic Therapies, and Expanding Generics Drive Competitive Differentiation

Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio?

NVS

Zacks

3 days ago

Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio?

Novartis Receives FDA Approval for Rhapsido (remibrutinib) for Chronic Spontaneous Urticaria

NVS

Insider Monkey

3 days ago

Novartis Receives FDA Approval for Rhapsido (remibrutinib) for Chronic Spontaneous Urticaria

NVS

Argus Research

3 days ago

Analyst Report: Alcon Inc.

Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines?

NVS

Zacks

6 days ago

Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines?

NVS

Zacks

7 days ago

The Zacks Analyst Blog Highlights SAP, Novartis, Philip Morris International, ImmuCell and ClearOne

Novartis (SWX:NOVN): Evaluating Fair Value as Investor Optimism Drives Recent Gains

NVS

Simply Wall St.

7 days ago

Novartis (SWX:NOVN): Evaluating Fair Value as Investor Optimism Drives Recent Gains

Top Stock Reports for SAP, Novartis & Philip Morris

NVS

Zacks

8 days ago

Top Stock Reports for SAP, Novartis & Philip Morris

Should You Buy Novartis Stock Before October 28?

NVS

Barchart

8 days ago

Should You Buy Novartis Stock Before October 28?

Here's Why Novartis (NVS) is a Strong Value Stock

NVS

Zacks

8 days ago

Here's Why Novartis (NVS) is a Strong Value Stock

3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal

NVS

Zacks

8 days ago

3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal

Is There Still Room for Growth in Novartis Shares After Year-to-Date Rally?

NVS

Simply Wall St.

8 days ago

Is There Still Room for Growth in Novartis Shares After Year-to-Date Rally?

Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 Billion by 2033 as Gene Therapies and RNA-based Treatments Redefine Patient Outcomes

NVS

PR Newswire

9 days ago

Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 Billion by 2033 as Gene Therapies and RNA-based Treatments Redefine Patient Outcomes

Rare Disease Therapeutics Market to Surpass US$ 495.27 Billion by 2033 as Gene Therapy, RNA-based Drugs, and Biologics Transform Patient Care

NVS

PR Newswire

9 days ago

Rare Disease Therapeutics Market to Surpass US$ 495.27 Billion by 2033 as Gene Therapy, RNA-based Drugs, and Biologics Transform Patient Care

HS Connect Makes History with Times Square’s First Patient-Led Runway Show

NVS

Business Wire

9 days ago

HS Connect Makes History with Times Square’s First Patient-Led Runway Show

NVS

MT Newswires

9 days ago

Jade Biosciences Unveils JADE201 Antibody to Potentially Treat Autoimmune Diseases

3 Reasons Growth Investors Will Love Novartis (NVS)

NVS

Zacks

10 days ago

3 Reasons Growth Investors Will Love Novartis (NVS)

Luckie Names Scott Gelber Chief Executive Officer to Lead Next Phase of Agency's Growth

NVS

PR Newswire

10 days ago

Luckie Names Scott Gelber Chief Executive Officer to Lead Next Phase of Agency's Growth

Why Novartis (NVS) is a Top Momentum Stock for the Long-Term

NVS

Zacks

10 days ago

Why Novartis (NVS) is a Top Momentum Stock for the Long-Term

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

NVS

Zacks

10 days ago

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

2 Surefire Dividend Stocks to Buy for the Long Haul

NVS

Motley Fool

12 days ago

2 Surefire Dividend Stocks to Buy for the Long Haul

NVS

Zacks

13 days ago

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?

NVS

Zacks

14 days ago

Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?

NVS

MT Newswires

14 days ago

Kinaxis to Deploy Maestro Platform for Sweden's Sobi to Boost Rare Disease Supply Chains

Why Drug Stocks Are Celebrating Trump's 100% Pharmaceutical Tariff

NVS

Investor's Business Daily

15 days ago

Why Drug Stocks Are Celebrating Trump's 100% Pharmaceutical Tariff

Pfizer Stock, Other Drugmakers Rally Again

NVS

The Wall Street Journal

15 days ago

Pfizer Stock, Other Drugmakers Rally Again

Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?

NVS

Zacks

15 days ago

Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?

2025 Dermatology Treatment and Care Market Analysis Report with Impact Analysis of US Tariffs Featuring Novartis, Pfizer, Amgen, GSK, F. Hoffmann-La Roche, J&J, AbbVie, Merck, Bayer, Sanofi

NVS

GlobeNewswire

15 days ago

2025 Dermatology Treatment and Care Market Analysis Report with Impact Analysis of US Tariffs Featuring Novartis, Pfizer, Amgen, GSK, F. Hoffmann-La Roche, J&J, AbbVie, Merck, Bayer, Sanofi

NCCN Awards Funding to Improve Care for People with Breast Cancer

NVS

PR Newswire

15 days ago

NCCN Awards Funding to Improve Care for People with Breast Cancer

NVS

MT Newswires

15 days ago

Immatics Names Venkat Ramanan CFO

Immatics Appoints Venkat Ramanan as Chief Financial Officer

NVS

GlobeNewswire

15 days ago

Immatics Appoints Venkat Ramanan as Chief Financial Officer

Iron Overload Syndrome Market Report 2025-2035, Profiles of Chiesi Group, Novartis, PHARMACOSMOS, Protagonist Therapeutics, Regeneron Pharmaceuticals

NVS

GlobeNewswire

15 days ago

Iron Overload Syndrome Market Report 2025-2035, Profiles of Chiesi Group, Novartis, PHARMACOSMOS, Protagonist Therapeutics, Regeneron Pharmaceuticals

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

NVS

The Wall Street Journal

15 days ago

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

NVS

MT Newswires

15 days ago

Novartis Receives FDA Approval for Skin Condition Treatment

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

NVS

PR Newswire

16 days ago

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

Amanda Nolen joins Totara as Non-Executive Director

NVS

PR Newswire

16 days ago

Amanda Nolen joins Totara as Non-Executive Director

Novartis Singapore and the Singapore Heart Foundation Launch 'Beat the Block' Campaign to Raise Awareness of High Blood Cholesterol

NVS

PR Newswire

16 days ago

Novartis Singapore and the Singapore Heart Foundation Launch 'Beat the Block' Campaign to Raise Awareness of High Blood Cholesterol

Pharma's Direct-To-Patient Wave Hits Novartis Next

NVS

Benzinga

17 days ago

Pharma's Direct-To-Patient Wave Hits Novartis Next

dHealth Intelligence Launches Revolutionary AI Agent That Transforms Personal Healthcare Management

NVS

ACCESS Newswire

17 days ago

dHealth Intelligence Launches Revolutionary AI Agent That Transforms Personal Healthcare Management

Novartis to Launch Direct-to-Patient Platform for Cosentyx in U.S.

NVS

The Wall Street Journal

17 days ago

Novartis to Launch Direct-to-Patient Platform for Cosentyx in U.S.

NVS

MT Newswires

17 days ago

Novartis to Launch US Direct-to-Patient Platform for Cosentyx

NVS

MT Newswires

17 days ago

Novartis Unit Begins Tender Offer to Acquire Tourmaline Bio

Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US

NVS

GlobeNewswire

17 days ago

Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US

Novartis announces commencement of tender offer to acquire Tourmaline Bio

NVS

GlobeNewswire

17 days ago

Novartis announces commencement of tender offer to acquire Tourmaline Bio

Novartis AG (NVS) To Present New Data on Kesimpta at ECTRIMS 2025 in Barcelona

NVS

Insider Monkey

17 days ago

Novartis AG (NVS) To Present New Data on Kesimpta at ECTRIMS 2025 in Barcelona

NVS

Morningstar Research

20 days ago

Analyst Report: Novartis AG

Big Pharma Unfazed by Trump Tariffs, but Small Biotechs Face Vulnerability

NVS

The Wall Street Journal

20 days ago

Big Pharma Unfazed by Trump Tariffs, but Small Biotechs Face Vulnerability

Eli Lilly, Merck, Pfizer Stocks Rise After Trump Unveils Pharma Tariffs

NVS

The Wall Street Journal

20 days ago

Eli Lilly, Merck, Pfizer Stocks Rise After Trump Unveils Pharma Tariffs

NVS

MT Newswires

20 days ago

Amneal Pharmaceuticals Files Biologics License Application for Xolair Biosimilar

NVS

MT Newswires

20 days ago

Novartis Says Won't be Impacted by 100% Tariff on Branded Pharmaceutical Products

Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)

NVS

GlobeNewswire

20 days ago

Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)

Is pharma’s IRA pricing battle running out of steam?

NVS

Pharma Voice

20 days ago

Is pharma’s IRA pricing battle running out of steam?

Trump Plans New Tariff Push With 100% Rate on Patented Drugs

NVS

Bloomberg

20 days ago

Trump Plans New Tariff Push With 100% Rate on Patented Drugs

Roche, Novartis underline U.S. plans after Trump pharma tariff announcement

NVS

Reuters

20 days ago

Roche, Novartis underline U.S. plans after Trump pharma tariff announcement

European pharma shares drop after Trump threatens more tariffs

NVS

Reuters

20 days ago

European pharma shares drop after Trump threatens more tariffs

Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025

NVS

GlobeNewswire

20 days ago

Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025

Regenerative Medicine Industry Trends and Growth Strategies, 2025-2030 Featuring Novartis, Biogen, GlaxoSmithKline, Baxter International, and Boehringer Ingelheim

NVS

GlobeNewswire

21 days ago

Regenerative Medicine Industry Trends and Growth Strategies, 2025-2030 Featuring Novartis, Biogen, GlaxoSmithKline, Baxter International, and Boehringer Ingelheim

Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody

NVS

GlobeNewswire

21 days ago

Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody

Humana Extends TailorCare Tie-Up to Enhance MA Member Health

NVS

Zacks

22 days ago

Humana Extends TailorCare Tie-Up to Enhance MA Member Health

BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL

NVS

Zacks

22 days ago

BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL

Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations

NVS

GlobeNewswire

22 days ago

Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations

Novartis (SWX:NOVN): Evaluating Current Valuation During a Period of Market Caution

NVS

Simply Wall St.

22 days ago

Novartis (SWX:NOVN): Evaluating Current Valuation During a Period of Market Caution

New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies

NVS

GlobeNewswire

22 days ago

New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies

MLAB Biosciences Expands Scientific Advisory Board with Appointments of Peter Kang and Kathryn Wagner, Deepening Scientific Expertise in Neuromuscular Medicine

NVS

PR Newswire

23 days ago

MLAB Biosciences Expands Scientific Advisory Board with Appointments of Peter Kang and Kathryn Wagner, Deepening Scientific Expertise in Neuromuscular Medicine

Roche CEO, pharma execs to meet with Swiss government over US tariffs

NVS

Reuters

24 days ago

Roche CEO, pharma execs to meet with Swiss government over US tariffs

Cellares Appoints Former Kite Global Ops Leader, Christopher McDonald, to Board of Advisors

NVS

Business Wire

24 days ago

Cellares Appoints Former Kite Global Ops Leader, Christopher McDonald, to Board of Advisors

Novartis chief eyes ways to end higher US drug prices: media

NVS

AFP

a month ago

Novartis chief eyes ways to end higher US drug prices: media

Novartis has stockpiles to withstand potential Trump tariffs, CEO says

NVS

Reuters

a month ago

Novartis has stockpiles to withstand potential Trump tariffs, CEO says

INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream

NVS

Zacks

a month ago

INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream

RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline

NVS

Zacks

a month ago

RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline

Why Novartis (NVS) is a Top Value Stock for the Long-Term

NVS

Zacks

a month ago

Why Novartis (NVS) is a Top Value Stock for the Long-Term

Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year?

NVS

Zacks

a month ago

Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year?

INCY Announces New Late-Stage Data on Skin Disease Drug

NVS

Zacks

a month ago

INCY Announces New Late-Stage Data on Skin Disease Drug

Monte Rosa's Stock Gains on Signing $5.7B Licensing Deal With Novartis

NVS

Zacks

a month ago

Monte Rosa's Stock Gains on Signing $5.7B Licensing Deal With Novartis

Monte Rosa Therapeutics (GLUE) Soars 44.1%: Is Further Upside Left in the Stock?

NVS

Zacks

a month ago

Monte Rosa Therapeutics (GLUE) Soars 44.1%: Is Further Upside Left in the Stock?

Does the Recent 4.6% Dip Signal Opportunity for Novartis in 2025?

NVS

Simply Wall St.

a month ago

Does the Recent 4.6% Dip Signal Opportunity for Novartis in 2025?

$Europe Refractory Epilepsy Treatment Research Report 2025 | Market to More Than Double to Reach $2.82 Billion by 2035, Driven by CBD Growth, Uptake of Neuromodulation Therapies, Strong R&D Pipeline$

NVS

GlobeNewswire

a month ago

Europe Refractory Epilepsy Treatment Research Report 2025 | Market to More Than Double to Reach $2.82 Billion by 2035, Driven by CBD Growth, Uptake of Neuromodulation Therapies, Strong R&D Pipeline

Novartis returns to Monte Rosa for second time in a year with $5.7bn deal

NVS

Pharmaceutical Technology

a month ago

Novartis returns to Monte Rosa for second time in a year with $5.7bn deal

Monte Rosa Rockets 50% on $5.7B Novartis Licensing Deal

NVS

GuruFocus.com

a month ago

Monte Rosa Rockets 50% on $5.7B Novartis Licensing Deal

Novartis AG (NVS) Strengthens Cardiovascular Unit with Tourmaline Bio Acquisition

NVS

Insider Monkey

a month ago

Novartis AG (NVS) Strengthens Cardiovascular Unit with Tourmaline Bio Acquisition

NVS

MT Newswires

a month ago

Traders Cautious Ahead of Fed Meeting, Driving Muted Premarket Action for US Equity Futures

NVS

The Bergen Record

a month ago

3 firms to lay off hundreds of North Jersey-based employees

NVS

Investing.com

a month ago

Monte Rosa surges premarket on Novartis collaboration deal

NVS

MT Newswires

a month ago

Top Premarket Gainers

NVS

MT Newswires

a month ago

Monte Rosa Therapeutics Partners With Novartis on Immune Disease Degraders; Shares Rise Pre-Bell

Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics

NVS

Reuters

a month ago

Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics

Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases

NVS

GlobeNewswire

a month ago

Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases

Molson Coors downgraded, GM upgraded: Wall Street's top analyst calls

NVS

The Fly

a month ago

Molson Coors downgraded, GM upgraded: Wall Street's top analyst calls

More leaders are recognizing the ‘power of small teams’

NVS

Fortune

a month ago

More leaders are recognizing the ‘power of small teams’

NVS

Zacks

a month ago

Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer

FDA Approves BioArctic (OM:BIOA B) Lecanemab Injection For Alzheimer's

NVS

Simply Wall St.

a month ago

FDA Approves BioArctic (OM:BIOA B) Lecanemab Injection For Alzheimer's

Top 20 biopharma market caps fall 5.7% amid industry challenges

NVS

Pharmaceutical Technology

a month ago

Top 20 biopharma market caps fall 5.7% amid industry challenges

5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds

NVS

Zacks

a month ago

5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds

NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline

NVS

Zacks

a month ago

NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline

Chronic Myelomonocytic Leukemia Market Analysis and Forecast Report 2025-2035, with Profiles of AbbVie, GlaxoSmithKline, Incyte, Jazz Pharmaceuticals, Novartis, Stemline Therapeutics, and More

NVS

GlobeNewswire

a month ago

Chronic Myelomonocytic Leukemia Market Analysis and Forecast Report 2025-2035, with Profiles of AbbVie, GlaxoSmithKline, Incyte, Jazz Pharmaceuticals, Novartis, Stemline Therapeutics, and More

Pharma’s new boomtown? Why drugmakers are setting up shop in a small Swiss city.

NVS

Pharma Voice

a month ago

Pharma’s new boomtown? Why drugmakers are setting up shop in a small Swiss city.

H.C. Wainwright Reiterated a Buy on Arrowhead Pharmaceuticals (ARWR)

NVS

Insider Monkey

a month ago

Latest Novartis AG (NVS) News on October 16, 2025

Share on Social Networks: